NLS Global report

AstraZeneca has opened its newest global strategic R&D center in Kendall Square, Cambridge, Massachusetts. It is part of a USD 1 billion investment that will grow the company's workforce in the state by more than 50%.

US President Donald Trump said on Friday September 18, 2026, that his administration plans to recommend that vaccine makers split certain childhood vaccines into five smaller doses given six months apart, which he expects to sharply reduce autism. He did not name the vaccines or cite evidence.

More than 40% of women in the US say their health has limited their career, and the share rises to 66% among women who cannot get the care they need, according to a new Gallup survey conducted in partnership with Pivotal.

With a new EUR 61 million facility in Vilnius, Northway Biotech becomes the first dedicated cell therapy and personalized medicine CDMO in the Baltics – a development that also expands manufacturing capacity within reach of the Nordic biotech sector.

The US FDA has approved RASONQUE (daraxonrasib), Revolution Medicines' once-daily pill, for adults with previously treated metastatic pancreatic adenocarcinoma — the first medicine to directly target RAS, the protein driving most pancreatic cancers.

AstraZeneca and partner Amgen have reported that Tezspire (tezepelumab) met both co-primary and all key secondary endpoints in the Phase III CROSSING trial in eosinophilic esophagitis (EoE), positioning the anti-TSLP antibody for a potential new indication beyond its existing approvals in severe asthma and chronic rhinosinusitis with nasal polyps.